Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019002 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
A Phase 1 study of Glioblastoma Multiforme (GBM), sponsored by Susan Chang.
- Active
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04019002 is a Phase 1 study of Glioblastoma Multiforme (GBM) that is active but no longer recruiting, run by Susan Chang. The registered enrollment target is 17 participants, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04019002, a Phase 1 study of Glioblastoma Multiforme (GBM), is active but no longer recruiting, sponsored by Susan Chang.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized 13C pyruvate, to obtain dynamic metabolic imaging.
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C Pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019002
The ClinicalTrials.gov registry entry for NCT04019002 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 5 other Glioblastoma Multiforme (GBM) trials with a reported enrollment target (75% lower). The listed sponsor is Susan Chang, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme (GBM) appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C Pyruvate is the first listed.
NCT04019002 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04019002 about?
NCT04019002 is a clinical study titled "Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma". The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose t...
What is the current status of trial NCT04019002?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-11-19. Estimated completion is 2025-09-30.
What conditions does trial NCT04019002 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme (GBM).
What interventions are being tested in trial NCT04019002?
The interventions under investigation include: Hyperpolarized 13C Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04019002?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04019002 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme (GBM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
RECRUITING · Phase 1
-
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
ACTIVE NOT RECRUITING · Phase 1
-
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
COMPLETED · Phase 1
-
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
COMPLETED · Phase 1
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.